Long-term prothionamide compliance: a study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid.
Ellard
G A
GA
Kiran
K U
KU
Stanley
J N
JN
D000293:Adolescent; D000328:Adult; D003622:Dapsone / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007194:India; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects; D007539:Isonicotinic Acids / Q000008:administration & dosage*; D015440:Leprosy, Lepromatous / Q000188:drug therapy / Q000652:urine; D015441:Leprosy, Tuberculoid / Q000188:drug therapy / Q000652:urine; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010349:Patient Compliance; D011515:Prothionamide / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
D007539:Isonicotinic Acids; D011515:Prothionamide; D003622:Dapsone; D007538:Isoniazid